Skip to main content
. 2016 Nov 3;8(9):15943–15951. doi: 10.18632/oncotarget.13056

Figure 2. Kaplan-Meier estimates of.

Figure 2

A. progression-free survival (PFS) and B. overall survival (OS) of patients with advanced non-small cell lung cancer that were treated. The differences in median PFS (HR 1.03, 95% CI 0.71-1.41, P = 0.98) and OS (HR 0.86, 95% CI 0.57–1.30) were not statistically significant between the nimotuzumab plus gefitinib and the gefitinib arm.